<p>Thoroughbred Financial Services LLC 在最近向美国证券交易委员会（SEC）提交的文件中表示，在第四季度削减了对 Viking Therapeutics, Inc.（NASDAQ:VKTX - 免费报告）股票的持股比例，减少幅度为 71.6%。该公司在出售了 16,051 股后，持有该生物技术公司 6,373 股股票。根据其最近的 SEC 文件，Thoroughbred Financial Services LLC 在 Viking Therapeutics 的持股价值为 256,000 美元。</p>
<p>获取 <strong>Viking Therapeutics</strong> 的提醒：</p>
<ul>
<li>目前哪个医疗保健股票是最佳买入？</li>
</ul>
<p>其他大型投资者最近也调整了对该公司的持股。S.A. Mason LLC 在第四季度将其在 Viking Therapeutics 的持股比例提高了 20.0%。S.A. Mason LLC 现在拥有 1,800 股该生物技术公司的股票，价值 72,000 美元，此前在该期间购买了额外的 300 股。Blue Trust Inc. 在第四季度将其在 Viking Therapeutics 的持股比例提高了 75.9%。Blue Trust Inc. 现在拥有 716 股该生物技术公司的股票，价值 29,000 美元，此前在上个季度获得了额外的 309 股。瑞士银行 Julius Baer &amp; Co. Ltd 在第四季度将其在 Viking Therapeutics 的持股比例提高了 7.4%。瑞士银行 Julius Baer &amp; Co. Ltd 现在拥有 4,980 股该生物技术公司的股票，价值 221,000 美元，此前在上个季度获得了额外的 345 股。亚利桑那州退休系统在第四季度将其在 Viking Therapeutics 的持股比例提高了 1.2%。亚利桑那州退休系统现在拥有 28,929 股该生物技术公司的股票，价值 1,164,000 美元，此前在上个季度获得了额外的 353 股。最后，Activest Wealth Management 在第四季度将其在 Viking Therapeutics 的持股比例提高了 24.1%。Activest Wealth Management 现在拥有 2,165 股该生物技术公司的股票，价值 87,000 美元，此前在上个季度购买了额外的 420 股。76.03% 的股票由机构投资者和对冲基金持有。</p>
<h2>分析师评级调整</h2>
<p>VKTX 最近成为几份分析师报告的主题。B. Riley 在 2 月 7 日的研究报告中重申了对 Viking Therapeutics 的 &#34;买入&#34; 评级，并将目标价下调至 96.00 美元（之前为 109.00 美元）。HC Wainwright 在 3 月 26 日的研究报告中重申了对 Viking Therapeutics 的 &#34;买入&#34; 评级，并设定了 102.00 美元的目标价。Scotiabank 在 2 月 13 日的报告中开始覆盖 Viking Therapeutics 的股票。他们对该公司给予了 &#34;行业表现优于大盘&#34; 的评级，并设定了 102.00 美元的目标价。花旗集团在 2 月 7 日的报告中开始覆盖 Viking Therapeutics 的股票。他们对该股票设定了 &#34;中性&#34; 评级和 38.00 美元的目标价。最后，Raymond James 在 2 月 6 日的研究报告中将 Viking Therapeutics 的目标价从 122.00 美元提高至 125.00 美元，并给予该公司 &#34;强力买入&#34; 的评级。一位投资分析师对该股票给予了卖出评级，一位给予了持有评级，十位给予了买入评级，一位给予了强力买入评级。根据 MarketBeat 的数据，Viking Therapeutics 目前的平均评级为 &#34;适度买入&#34;，平均目标价为 95.18 美元。</p>
<ul>
<li>MarketBeat 周回顾 – 03/17 - 03/21</li>
</ul>
<p><strong>查看我们关于 VKTX 的最新报告</strong></p>
<h2>Viking Therapeutics 股票下跌 6.6%</h2>
<p>VKTX 股票周一开盘价为 22.62 美元。该股票的 50 日移动平均线为 29.32 美元，200 日移动平均线为 45.06 美元。该股票的市值为 25.4 亿美元，市盈率为 -22.62，贝塔值为 0.84。Viking Therapeutics, Inc. 的 1 年低点为 20.20 美元，1 年高点为 81.86 美元。</p>
<ul>
<li>Viking Therapeutics 是下一个重磅 GLP-1 股票吗？</li>
</ul>
<p>Viking Therapeutics（NASDAQ:VKTX - 获取免费报告）最近在 2 月 5 日发布了季度财报。该生物技术公司报告每股收益为（$0.32），低于市场共识预期的（$0.27），差额为（$0.05）。在去年同期，该公司每股收益为（$0.25）。卖方分析师预测，Viking Therapeutics, Inc. 在当前年度将发布每股收益 -1.56。</p>
<h2>内部活动</h2>
<p>在相关消息中，董事 Sarah Kathryn Rouan 于 3 月 31 日星期一购买了 1,240 股该公司的股票。每股购买价格为 24.15 美元，总交易额为 29,946.00 美元。交易完成后，该董事现在直接拥有 1,240 股该公司的股票，价值约 29,946 美元。此次交易使其持股比例增加了 ∞。该交易已在向证券交易委员会的法律文件中披露，可以通过此超链接访问。4.70% 的股票由公司内部人士持有。</p>
<h2>Viking Therapeutics 公司简介</h2>
<p>（免费报告）</p>
<p>Viking Therapeutics, Inc. 是一家临床阶段的生物制药公司，专注于开发用于代谢和内分泌疾病的新疗法。该公司的主要药物候选者是 VK2809，一种口服可用的组织和受体亚型选择性激动剂，针对甲状腺激素受体 beta（TRß），目前正在进行 IIb 期临床试验，以治疗经活检确认的非酒精性脂肪性肝炎以及 NAFLD。</p>
<h2>了解更多</h2>
<ul>
<li>五只我们更看好的股票，胜过 Viking Therapeutics</li>
<li>消费品股票解析</li>
<li>Newsmax 的 IPO 反转：是 Meme 股票炒作还是增长潜力？</li>
<li>如何使用 MarketBeat 股票筛选器</li>
<li>迪士尼 2025 年股东：投资者的重要更新</li>
<li>如何知道购买哪种加密货币：投资者指南</li>
<li>Advance Auto Parts 股票：经典反弹的潜力</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9VktUWA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9VktUWA"/></p>
<p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快和最准确的报道。此故事在发布前已由 MarketBeat 的编辑团队审核。请将有关此故事的任何问题或评论发送至 contact@marketbeat.com.</em></p>
<h2>你现在应该投资 1,000 美元在 Viking Therapeutics 吗？</h2>
<p>在考虑 Viking Therapeutics 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄建议客户现在购买的股票，以便在更广泛的市场注意到之前……而 Viking Therapeutics 并不在名单上。</p>
<p>虽然 Viking Therapeutics 目前在分析师中获得了买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

Viking治疗

<p>Thoroughbred Financial Services LLC 将其在 Viking Therapeutics, Inc. (NASDAQ:VKTX) 的持股比例减少了 71.6%，在第四季度出售了 16,051 股，剩余 6,373 股，价值 256,000 美元。其他投资者也调整了他们的持股，其中 S.A. Mason LLC 和 Blue Trust Inc. 的增持幅度显著。分析师对 VKTX 的评级不一，普遍认为为 “适度买入”，平均目标价为 95.18 美元。该股票开盘价为 22.62 美元，下跌 6.6%，市值为 25.4 亿美元，最近的每股收益为 -0.32，未达到预期</p>

<p>Thoroughbred Financial Services LLC trimmed its stake in shares of Viking Therapeutics, Inc. (NASDAQ:VKTX - Free Report) by 71.6% in the fourth quarter, according to the company in its most recent filing with the SEC. The firm owned 6,373 shares of the biotechnology company's stock after selling 16,051 shares during the quarter. Thoroughbred Financial Services LLC's holdings in Viking Therapeutics were worth $256,000 as of its most recent SEC filing.</p>
<div class="lb-trans"><p>Thoroughbred Financial Services LLC 在最近向美国证券交易委员会（SEC）提交的文件中表示，在第四季度削减了对 Viking Therapeutics, Inc.（NASDAQ:VKTX - 免费报告）股票的持股比例，减少幅度为 71.6%。该公司在出售了 16,051 股后，持有该生物技术公司 6,373 股股票。根据其最近的 SEC 文件，Thoroughbred Financial Services LLC 在 Viking Therapeutics 的持股价值为 256,000 美元。</p>
</div><p>Get <strong>Viking Therapeutics</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>Viking Therapeutics</strong> 的提醒：</p>
</div><ul>
<li>Which Healthcare Stock Is the Best Buy Right Now?</li>
</ul>
<div class="lb-trans"><ul>
<li>目前哪个医疗保健股票是最佳买入？</li>
</ul>
</div><p>Other large investors also recently modified their holdings of the company. S.A. Mason LLC lifted its position in Viking Therapeutics by 20.0% during the fourth quarter. S.A. Mason LLC now owns 1,800 shares of the biotechnology company's stock worth $72,000 after purchasing an additional 300 shares during the period. Blue Trust Inc. boosted its position in shares of Viking Therapeutics by 75.9% during the 4th quarter. Blue Trust Inc. now owns 716 shares of the biotechnology company's stock worth $29,000 after acquiring an additional 309 shares in the last quarter. Bank Julius Baer &amp; Co. Ltd Zurich boosted its position in shares of Viking Therapeutics by 7.4% during the 4th quarter. Bank Julius Baer &amp; Co. Ltd Zurich now owns 4,980 shares of the biotechnology company's stock worth $221,000 after acquiring an additional 345 shares in the last quarter. Arizona State Retirement System increased its stake in Viking Therapeutics by 1.2% in the fourth quarter. Arizona State Retirement System now owns 28,929 shares of the biotechnology company's stock valued at $1,164,000 after acquiring an additional 353 shares during the last quarter. Finally, Activest Wealth Management raised its position in Viking Therapeutics by 24.1% during the fourth quarter. Activest Wealth Management now owns 2,165 shares of the biotechnology company's stock valued at $87,000 after purchasing an additional 420 shares in the last quarter. 76.03% of the stock is owned by institutional investors and hedge funds.</p>
<div class="lb-trans"><p>其他大型投资者最近也调整了对该公司的持股。S.A. Mason LLC 在第四季度将其在 Viking Therapeutics 的持股比例提高了 20.0%。S.A. Mason LLC 现在拥有 1,800 股该生物技术公司的股票，价值 72,000 美元，此前在该期间购买了额外的 300 股。Blue Trust Inc. 在第四季度将其在 Viking Therapeutics 的持股比例提高了 75.9%。Blue Trust Inc. 现在拥有 716 股该生物技术公司的股票，价值 29,000 美元，此前在上个季度获得了额外的 309 股。瑞士银行 Julius Baer &amp; Co. Ltd 在第四季度将其在 Viking Therapeutics 的持股比例提高了 7.4%。瑞士银行 Julius Baer &amp; Co. Ltd 现在拥有 4,980 股该生物技术公司的股票，价值 221,000 美元，此前在上个季度获得了额外的 345 股。亚利桑那州退休系统在第四季度将其在 Viking Therapeutics 的持股比例提高了 1.2%。亚利桑那州退休系统现在拥有 28,929 股该生物技术公司的股票，价值 1,164,000 美元，此前在上个季度获得了额外的 353 股。最后，Activest Wealth Management 在第四季度将其在 Viking Therapeutics 的持股比例提高了 24.1%。Activest Wealth Management 现在拥有 2,165 股该生物技术公司的股票，价值 87,000 美元，此前在上个季度购买了额外的 420 股。76.03% 的股票由机构投资者和对冲基金持有。</p>
</div><h2>Analyst Upgrades and Downgrades</h2>
<div class="lb-trans"><h2>分析师评级调整</h2>
</div><p>VKTX has been the topic of several recent analyst reports. B. Riley reiterated a &#34;buy&#34; rating and issued a $96.00 price target (down previously from $109.00) on shares of Viking Therapeutics in a research note on Friday, February 7th. HC Wainwright reiterated a &#34;buy&#34; rating and issued a $102.00 target price on shares of Viking Therapeutics in a research report on Wednesday, March 26th. Scotiabank began coverage on shares of Viking Therapeutics in a report on Thursday, February 13th. They issued a &#34;sector outperform&#34; rating and a $102.00 target price for the company. Citigroup assumed coverage on shares of Viking Therapeutics in a report on Friday, February 7th. They set a &#34;neutral&#34; rating and a $38.00 price target on the stock. Finally, Raymond James increased their price objective on shares of Viking Therapeutics from $122.00 to $125.00 and gave the company a &#34;strong-buy&#34; rating in a research note on Thursday, February 6th. One investment analyst has rated the stock with a sell rating, one has issued a hold rating, ten have assigned a buy rating and one has given a strong buy rating to the company's stock. According to data from MarketBeat, Viking Therapeutics presently has an average rating of &#34;Moderate Buy&#34; and an average target price of $95.18.</p>
<div class="lb-trans"><p>VKTX 最近成为几份分析师报告的主题。B. Riley 在 2 月 7 日的研究报告中重申了对 Viking Therapeutics 的 &#34;买入&#34; 评级，并将目标价下调至 96.00 美元（之前为 109.00 美元）。HC Wainwright 在 3 月 26 日的研究报告中重申了对 Viking Therapeutics 的 &#34;买入&#34; 评级，并设定了 102.00 美元的目标价。Scotiabank 在 2 月 13 日的报告中开始覆盖 Viking Therapeutics 的股票。他们对该公司给予了 &#34;行业表现优于大盘&#34; 的评级，并设定了 102.00 美元的目标价。花旗集团在 2 月 7 日的报告中开始覆盖 Viking Therapeutics 的股票。他们对该股票设定了 &#34;中性&#34; 评级和 38.00 美元的目标价。最后，Raymond James 在 2 月 6 日的研究报告中将 Viking Therapeutics 的目标价从 122.00 美元提高至 125.00 美元，并给予该公司 &#34;强力买入&#34; 的评级。一位投资分析师对该股票给予了卖出评级，一位给予了持有评级，十位给予了买入评级，一位给予了强力买入评级。根据 MarketBeat 的数据，Viking Therapeutics 目前的平均评级为 &#34;适度买入&#34;，平均目标价为 95.18 美元。</p>
</div><ul>
<li>MarketBeat Week in Review – 03/17 - 03/21</li>
</ul>
<div class="lb-trans"><ul>
<li>MarketBeat 周回顾 – 03/17 - 03/21</li>
</ul>
</div><p><strong>View Our Latest Report on VKTX</strong></p>
<div class="lb-trans"><p><strong>查看我们关于 VKTX 的最新报告</strong></p>
</div><h2>Viking Therapeutics Trading Down 6.6 %</h2>
<div class="lb-trans"><h2>Viking Therapeutics 股票下跌 6.6%</h2>
</div><p>Shares of VKTX stock opened at $22.62 on Monday. The stock has a 50-day moving average of $29.32 and a 200-day moving average of $45.06. The stock has a market cap of $2.54 billion, a price-to-earnings ratio of -22.62 and a beta of 0.84. Viking Therapeutics, Inc. has a 1-year low of $20.20 and a 1-year high of $81.86.</p>
<div class="lb-trans"><p>VKTX 股票周一开盘价为 22.62 美元。该股票的 50 日移动平均线为 29.32 美元，200 日移动平均线为 45.06 美元。该股票的市值为 25.4 亿美元，市盈率为 -22.62，贝塔值为 0.84。Viking Therapeutics, Inc. 的 1 年低点为 20.20 美元，1 年高点为 81.86 美元。</p>
</div><ul>
<li>Is Viking Therapeutics the Next Blockbuster GLP-1 Stock?</li>
</ul>
<div class="lb-trans"><ul>
<li>Viking Therapeutics 是下一个重磅 GLP-1 股票吗？</li>
</ul>
</div><p>Viking Therapeutics (NASDAQ:VKTX - Get Free Report) last posted its quarterly earnings data on Wednesday, February 5th. The biotechnology company reported ($0.32) earnings per share for the quarter, missing the consensus estimate of ($0.27) by ($0.05). During the same period in the prior year, the business posted ($0.25) EPS. Sell-side analysts forecast that Viking Therapeutics, Inc. will post -1.56 earnings per share for the current year.</p>
<div class="lb-trans"><p>Viking Therapeutics（NASDAQ:VKTX - 获取免费报告）最近在 2 月 5 日发布了季度财报。该生物技术公司报告每股收益为（$0.32），低于市场共识预期的（$0.27），差额为（$0.05）。在去年同期，该公司每股收益为（$0.25）。卖方分析师预测，Viking Therapeutics, Inc. 在当前年度将发布每股收益 -1.56。</p>
</div><h2>Insider Activity</h2>
<div class="lb-trans"><h2>内部活动</h2>
</div><p>In related news, Director Sarah Kathryn Rouan bought 1,240 shares of the company's stock in a transaction that occurred on Monday, March 31st. The shares were bought at an average price of $24.15 per share, for a total transaction of $29,946.00. Following the transaction, the director now directly owns 1,240 shares of the company's stock, valued at approximately $29,946. The trade was a ∞ increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities &amp; Exchange Commission, which can be accessed through this hyperlink. 4.70% of the stock is owned by company insiders.</p>
<div class="lb-trans"><p>在相关消息中，董事 Sarah Kathryn Rouan 于 3 月 31 日星期一购买了 1,240 股该公司的股票。每股购买价格为 24.15 美元，总交易额为 29,946.00 美元。交易完成后，该董事现在直接拥有 1,240 股该公司的股票，价值约 29,946 美元。此次交易使其持股比例增加了 ∞。该交易已在向证券交易委员会的法律文件中披露，可以通过此超链接访问。4.70% 的股票由公司内部人士持有。</p>
</div><h2>Viking Therapeutics Company Profile</h2>
<div class="lb-trans"><h2>Viking Therapeutics 公司简介</h2>
</div><p>(Free Report)</p>
<div class="lb-trans"><p>（免费报告）</p>
</div><p>Viking Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD.</p>
<div class="lb-trans"><p>Viking Therapeutics, Inc. 是一家临床阶段的生物制药公司，专注于开发用于代谢和内分泌疾病的新疗法。该公司的主要药物候选者是 VK2809，一种口服可用的组织和受体亚型选择性激动剂，针对甲状腺激素受体 beta（TRß），目前正在进行 IIb 期临床试验，以治疗经活检确认的非酒精性脂肪性肝炎以及 NAFLD。</p>
</div><h2>Read More</h2>
<div class="lb-trans"><h2>了解更多</h2>
</div><ul>
<li>Five stocks we like better than Viking Therapeutics</li>
<li>Consumer Discretionary Stocks Explained</li>
<li>Newsmax’s IPO Whiplash: Meme Stock Hype or Growth Potential?</li>
<li>How to Use the MarketBeat Stock Screener</li>
<li>Disney 2025 Shareholders: Major Updates for Investors</li>
<li>How to Know Which Cryptocurrency to Buy: A Guide for Investors</li>
<li>Advance Auto Parts Stock: A Classic Rebound Play in the Making</li>
</ul>
<div class="lb-trans"><ul>
<li>五只我们更看好的股票，胜过 Viking Therapeutics</li>
<li>消费品股票解析</li>
<li>Newsmax 的 IPO 反转：是 Meme 股票炒作还是增长潜力？</li>
<li>如何使用 MarketBeat 股票筛选器</li>
<li>迪士尼 2025 年股东：投资者的重要更新</li>
<li>如何知道购买哪种加密货币：投资者指南</li>
<li>Advance Auto Parts 股票：经典反弹的潜力</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9VktUWA" alt="" original-src="https://www.marketbeat.com/scripts/SECFilingChart.ashx?Prefix=NASDAQ&amp;Symbol=VKTX"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快和最准确的报道。此故事在发布前已由 MarketBeat 的编辑团队审核。请将有关此故事的任何问题或评论发送至 contact@marketbeat.com.</em></p>
</div><h2>Should You Invest $1,000 in Viking Therapeutics Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在 Viking Therapeutics 吗？</h2>
</div><p>Before you consider Viking Therapeutics, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑 Viking Therapeutics 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Viking Therapeutics wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄建议客户现在购买的股票，以便在更广泛的市场注意到之前……而 Viking Therapeutics 并不在名单上。</p>
</div><p>While Viking Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Viking Therapeutics 目前在分析师中获得了买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

Thoroughbred Financial Services LLC 出售了 Viking 治疗公司（NASDAQ:VKTX）的 16,051 股股票